168 results
Page 4 of 9
8-K
EX-99.1
vpaax4h
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
b9d5wtc2829l2u2h7
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
1po5a
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
EX-10.1
k735i
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
2j54y51w3v vj
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
EX-99.1
jl963jzzah
18 May 21
Other Events
3:09pm
8-K
EX-99.1
uconv2
11 May 21
Other Events
8:34am
8-K
EX-99.2
xngqj3aq8
11 May 21
Other Events
8:34am
8-K
EX-99.1
desdip86jukc6pa 5g
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm
8-K
EX-99.1
jmihe9
4 Mar 21
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
7:30am
8-K
EX-99.2
ngr3uc3r9o3vabd2po
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
ssftqt0
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
7zt3sewp
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm
8-K
EX-99.2
5nrb17fp
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm
8-K
EX-10.1
2cb1zosxf7sx533utip
30 Oct 20
Entry into a Material Definitive Agreement
5:02pm